+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Primary prevention of fatal ventricular arrhythmias with implantable cardioverter-defibrillator therapy--an analysis of implications based on MADIT II criteria



Primary prevention of fatal ventricular arrhythmias with implantable cardioverter-defibrillator therapy--an analysis of implications based on MADIT II criteria



Mcgill Journal of Medicine 9(1): 14-18



The primary aim of this retrospective study was to determine the proportion of patients with myocardial infarction (MI) who fulfil the criteria of the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II and the implications of MADIT II criteria in practice. We performed a retrospective analysis of three hundred and ninety four admissions to the Coronary Care Unit (CCU) of the Royal Infirmary of Edinburgh. We selected those with myocardial infarction (MI) and attempted to retrieve electronic copies of their echocardiogram reports. When available, these were used to assess requirement for primary-prevention Implantable Cardioverter Defibrillator (ICD) therapy based on reported left ventricular function. One hundred and ninety patients were admitted to the CCU with a diagnosis of MI. Of these, 100 patients (51.5%) had an echocardiogram. Requirement for ICD therapy was unlikely in 87 (87%), probable in 6 (6%) and necessary in 7 (7%). Since a significant number of patients in the probable category were also likely to meet MADIT II criteria, we concluded that the proportion of patients requiring primary-prevention ICD therapy would be no less than 7% and more likely to be 13%. In the context of a busy teaching hospital, a figure of 13% for the requirement of ICD therapy in MI patients represents annual implantation activity of at least 100 per million. This is likely to have very significant resource implications.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055181081

Download citation: RISBibTeXText

PMID: 19529803


Related references

Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. Journal of the American College of Cardiology 58(14): 1485-1496, 2011

Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention. Yearbook of Cardiology 2012: 478-480, 2012

Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention?. Journal of the American College of Cardiology 61(25): 2542-2550, 2013

Compliance to MADIT and MUSTT criteria for implantable cardioverter defibrillator therapy in the pre-SCD-Heft and MADIT II era. Data from a multicenter Italian study. International Journal of Cardiology 144(2): 268-269, 2010

Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death. American Journal of Cardiology 111(9): 1319-1323, 2013

Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study). Circulation. Arrhythmia and Electrophysiology 5(1): 147-154, 2012

Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular dysfunction. A pooled analysis of 10 primary prevention trials. Acc Current Journal Review 14(4): 44-0, 2005

Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: Implications for antiarrhythmic therapy and driving restrictions. Journal of the American College of Cardiology 37(7): 1910-1915, 2001

Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. Journal of the American College of Cardiology 44(11): 2166-2172, 2004

Chronic total occlusion of an infarct-related artery: a new predictor of ventricular arrhythmias in primary prevention implantable cardioverter defibrillator patients. Europace, 2016

Chronic total occlusion of an infarct-related artery: a new predictor of ventricular arrhythmias in primary prevention implantable cardioverter defibrillator patients. Europace 19(2): 267-274, 2017

Entropy of cardiac repolarization predicts ventricular arrhythmias and mortality in patients receiving an implantable cardioverter-defibrillator for primary prevention of sudden death. Europace 18(12): 1818-1828, 2016

Patients who receive an implantable cardioverter defibrillator for MADIT-II criteria in clinical practice are different from patients enrolled in MADIT-II. 2007

An impaired renal function and advanced heart failure represent independent predictors of the incidence of malignant ventricular arrhythmias in patients with an implantable cardioverter/defibrillator for primary prevention. Europace 12(10): 1439-1445, 2010

Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients?. Journal of Cardiovascular Electrophysiology 21(3): 231-235, 2010